News
NARI
37.22
-1.87%
-0.71
Weekly Report: what happened at NARI last week (0415-0419)?
Weekly Report · 1d ago
BUZZ-Truist bets on a 'beat & raise' Q1 for some med-tech players
Brokerage Truist Securities expects Q1 results beat and forecast raises for medical device makers Boston Scientific Corp BSX.N and Intuitive Surgical. Truist believes medical-technology sector will see rising earnings this quarter. Medical device makers have been benefitting from a resurgence in demand for joint replacements.
Reuters · 04/15 14:54
Weekly Report: what happened at NARI last week (0408-0412)?
Weekly Report · 04/15 09:22
Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down
Needham sees BSX, CNMD, RMD and Surmodics beating Street, despite medtech slow down. Needham estimates medtech sales grew less than expected in Q1, but that Boston Scientific, CONMED and ResMed should still beat the Street. The investment firm says medtech market only grew by 5.3% in the first quarter of 2024.
Seeking Alpha · 04/14 21:56
What 8 Analyst Ratings Have To Say About Inari Medical
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. The company has an average 12-month price target of $66.75. 8 analysts have expressed a variety of opinions on Inari Medical over the past quarter. The average price target has decreased by 8.06% from the previous $72.60.
Benzinga · 04/12 17:01
Inari Medical Is Maintained at Buy by Canaccord Genuity
Dow Jones · 04/12 16:10
Inari Medical Price Target Maintained With a $75.00/Share by Canaccord Genuity
Dow Jones · 04/12 16:10
The Implied Analyst 12-Month Target For SPSM
NASDAQ · 04/12 10:20
Inari Medical Announces the Release of 2023 Ethos and Sustainability Report
Inari Medical, Inc. Releases its 2023 Ethos and Sustainability Report. The report highlights Inari's commitment to its ethos and environmental, social and governance initiatives. Inari is a medical device company with a mission to treat and transform the lives of patients.
Barchart · 04/11 15:05
A Leaner AngioDynamics Is A High-Risk Execution-Driven Story
AngioDynamics has sold low-growth businesses, shifted to an outsourced manufacturing model, and refocused on cardiovascular and oncological care for potential growth. Recent approval of the AlphaVac F18 mechanical thrombectomy system for pulmonary embolism presents a significant opportunity in a growing market. The company's historical execution challenges raise concerns, but there is potential for a stronger, more profitable Angiodynamics.
Seeking Alpha · 04/09 20:49
Why You Should Retain Inari Medical (NARI) Stock for Now
NASDAQ · 04/09 15:04
Weekly Report: what happened at NARI last week (0401-0405)?
Weekly Report · 04/08 09:24
Inari Medical, Inc.: Statement of acquisition of beneficial ownership by individuals
Press release · 04/03 21:13
Analysts Have Conflicting Sentiments on These Healthcare Companies: Inari Medical (NARI) and Roivant Sciences (ROIV)
TipRanks · 04/03 09:03
INARI MEDICAL STRENGTHENS SENIOR LEADERSHIP TEAM WITH ADDITION OF TWO EXECUTIVES
Reuters · 04/02 20:05
Weekly Report: what happened at NARI last week (0325-0329)?
Weekly Report · 04/01 09:23
Market Cap Game Show: Andy Cross vs. Bill Mann
Andy Cross and Bill Mann face off for our first ever Market Cap Game Show world championships. The Motley Fool investing gurus face off in the final two weeks of March Madness on the Rule Breaker Investing podcast. This is the first ever world championship for the market cap game show. Andy Cross says he has competed against a world champion.
The Motley Fool · 03/30 11:45
Inari Medical (NARI) Up 4% Since Last Earnings Report: Can It Continue?
NASDAQ · 03/29 15:30
Inari Medical: Buy On Growing TAM
Inari Medical, Inc.'s share price has dropped due to a Department of Justice investigation on doctor payment practices. Inari is the leader in the treatment of venous thromboembolism. The company has a strong growth rate and is coming out with new products to grow their TAM. The medical device company has high potential operating margins and strong growth. NARI is one of the top medical device stocks to own for 2024.
Seeking Alpha · 03/27 20:05
BUZZ-AppFolio jumps to record high on S&P MidCap inclusion
AppFolio Inc's APPF.O shares jump as much as 11.9% to record high on S&P MidCap inclusion. Online property management software provider set to join S&p MidCap 400 index .IDX week. APPF to replace Inari Medical NARI.O in IDX.
Reuters · 03/26 16:13
More
Webull provides a variety of real-time NARI stock news. You can receive the latest news about Inari Medical, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About NARI
Inari Medical, Inc. is a medical device company. The Company’s products primarily consist of ClotTriever and FlowTriever systems, which are catheter-based mechanical thrombectomy systems that are used for the treatment of the venous thromboembolism (VTE) deep vein thrombosis (DVT), and pulmonary embolism (PE). Its InThrill system is used for the removal of emboli and thrombi from the peripheral vasculature. The LimFlow system is indicated for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and are at risk of major amputation. It also offers RevCore thrombectomy catheter, which is a thrombectomy device for venous stent thrombosis, Triever 16 Curve catheter, which is used for venous thrombus removal, and ClotTriever Bold catheter, which is used for DVT and the removal of acute and chronic clots in the peripheral vasculature. Its ClotTriever XL, which is a catheter for efficient clot removal with minimal blood loss.